Canine mast cell tumours part I: Clinical and survival outcomes
VS Tamlin, CDK Bottema, L Woolford… - Veterinary Medicine …, 2022 - Wiley Online Library
Background Dogs have a species‐specific susceptibility for developing mast cell tumours
(MCTs). Mutations in the KIT proto‐oncogene (KIT) are known to contribute to the neoplastic …
(MCTs). Mutations in the KIT proto‐oncogene (KIT) are known to contribute to the neoplastic …
[HTML][HTML] Canine mast cell tumours part I: Clinical and survival outcomes
VS Tamlin, CDK Bottema, L Woolford… - Veterinary Medicine …, 2022 - ncbi.nlm.nih.gov
Background Dogs have a species‐specific susceptibility for developing mast cell tumours
(MCTs). Mutations in the KIT proto‐oncogene (KIT) are known to contribute to the neoplastic …
(MCTs). Mutations in the KIT proto‐oncogene (KIT) are known to contribute to the neoplastic …
Canine mast cell tumours part I: Clinical and survival outcomes.
VS Tamlin, CDK Bottema, L Woolford… - … Medicine & Science, 2022 - search.ebscohost.com
Background: Dogs have a species‐specific susceptibility for developing mast cell tumours
(MCTs). Mutations in the KIT proto‐oncogene (KIT) are known to contribute to the neoplastic …
(MCTs). Mutations in the KIT proto‐oncogene (KIT) are known to contribute to the neoplastic …
Canine mast cell tumours Part I: clinical and survival outcomes.
VS Tamlin, CDK Bottema, L Woolford, EC Dobson… - 2022 - cabidigitallibrary.org
Background: Dogs have a species-specific susceptibility for developing mast cell tumours
(MCTs). Mutations in the KIT proto-oncogene (KIT) are known to contribute to the neoplastic …
(MCTs). Mutations in the KIT proto-oncogene (KIT) are known to contribute to the neoplastic …
Canine mast cell tumours part I: Clinical and survival outcomes
VS Tamlin, CDK Bottema, L Woolford, EC Dobson… - 2022 - agris.fao.org
Background Dogs have a species‐specific susceptibility for developing mast cell tumours
(MCTs). Mutations in the KIT proto‐oncogene (KIT) are known to contribute to the neoplastic …
(MCTs). Mutations in the KIT proto‐oncogene (KIT) are known to contribute to the neoplastic …
Canine mast cell tumours part I: Clinical and survival outcomes.
VS Tamlin, CDK Bottema, L Woolford… - Veterinary Medicine …, 2022 - europepmc.org
Background Dogs have a species-specific susceptibility for developing mast cell tumours
(MCTs). Mutations in the KIT proto-oncogene (KIT) are known to contribute to the neoplastic …
(MCTs). Mutations in the KIT proto-oncogene (KIT) are known to contribute to the neoplastic …
Canine mast cell tumours part I: Clinical and survival outcomes
VS Tamlin, CDK Bottema, L Woolford… - Veterinary …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Dogs have a species-specific susceptibility for developing mast cell tumours
(MCTs). Mutations in the KIT proto-oncogene (KIT) are known to contribute to the neoplastic …
(MCTs). Mutations in the KIT proto-oncogene (KIT) are known to contribute to the neoplastic …
Canine mast cell tumours part I: Clinical and survival outcomes
VS Tamlin, CDK Bottema, L Woolford… - Veterinary Medicine …, 2022 - search.proquest.com
Background Dogs have a species‐specific susceptibility for developing mast cell tumours
(MCTs). Mutations in the KIT proto‐oncogene (KIT) are known to contribute to the neoplastic …
(MCTs). Mutations in the KIT proto‐oncogene (KIT) are known to contribute to the neoplastic …